医学临床研究
  2025年6月8日 星期日           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2024, Vol. 41 Issue (1): 74-77    DOI: 10.3969/j.issn.1671-7171.2024.01.020
  论著 本期目录 | 过刊浏览 | 高级检索 |
血浆溶血磷脂酸受体1水平对高血压脑出血患者预后的预测价值
刘涛, 张辉, 徐凡叶*
西安大兴医院,陕西 西安 710016
The Predictive Value of Plasma Lysophosphatidic Acid Receptor 1 Levels on the Prognosis of Hypertensive Intracerebral Hemorrhage Patients
LIU Tao, ZHANG Hui, XU Fanye
Department of Respiration,Xi'an Daxing Hospital,Xi'an Shaanxi 710016
全文: PDF (1202 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】 探讨血浆溶血磷脂酸受体1(LPAR1)水平对高血压脑出血患者预后的预测价值。【方法】 选择2016年3月至2020年3月本院收治的130例高血压脑出血患者(观察组),另选同期在本院体检的50例健康者为对照组。采用酶联免疫吸附法检测两组血浆LPAR1水平,根据观察组患者发病30 d后的格拉斯哥预后量表(GOS)评分分为预后良好组(n=67)和预后不良组(n=63)。观察组患者的预后不良影响因素采用多因素Logistic回归进行分析,绘制受试者工作特征(ROC)曲线,评估血浆LPAR1水平与高血压脑出血患者预后不良的预测价值。【结果】 观察组血浆LPAR1水平高于对照组,差异有统计学意义(P<0.05)。预后良好组、预后不良组患者的出血量、美国国立卫生研究院卒中量表(NIHSS)评分及治疗方案比较,差异有统计学意义(P<0.05)。预后不良组患者血浆LPAR1水平高于预后良好组,差异有统计学意义(P<0.05)。多因素Logistic回归分析显示,LPAR1>4.22 μg/L、NIHSS评分>(23.62±2.55)分均是高血压脑出血患者预后不良的独立危险因素(P<0.05)。ROC曲线分析显示,血浆LPAR1水平诊断高血压脑出血疾病患者预后不良的AUC为0.857(95%CI:0.753~0.869),截断值为3.68 μmol/L,其灵敏度、特异度分别为81.3%、85.6%。【结论】 血浆LPAR1水平对高血压脑出血疾病患者预后有一定预测价值,可为临床早期评估患者预后提供一定参考。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
刘涛
张辉
徐凡叶
关键词 颅内出血,高血压性受体,溶血磷脂酸/血液预后    
Abstract:【Objective】 To explore the predictive value of plasma lysophosphatidic acid receptor 1 (LPAR1) levels on the prognosis of hypertensive intracerebral hemorrhage patients. 【Methods】 A total of 130 patients with hypertensive intracerebral hemorrhage admitted to our hospital from March 2016 to March 2020 were selected as the observation group, and 50 healthy individuals who underwent physical examinations at our hospital during the same period were selected as the control group. The plasma LPAR1 levels of two groups were detected using enzyme-linked immunosorbent assay (ELISA), and all patients were divided into a good prognosis group (n=67) and a poor prognosis group (n=63) based on the Glasgow Outcome Scale (GOS) scores after 30 days of onset. The factors affecting the poor prognosis of patients in the observation group were analyzed using multiple logistic regression, and the receiver operating characteristic (ROC) curve was plotted to evaluate the predictive value of plasma LPAR1 levels and poor prognosis in patients with hypertensive intracerebral hemorrhage. 【Results】 The plasma LPAR1 levels in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). The difference in bleeding volume, NIHSS score, and treatment plan between the group with good prognosis and the group with poor prognosis was statistically significant (P<0.05). The plasma LPAR1 levels in patients with poor prognosis were higher than those in those with good prognosis, and the difference was statistically significant (P<0.05). Multivariate logistic regression analysis showed that LPAR1>4.22 μg/L and NIHSS score>(23.62±2.55) scores were independent risk factors for poor prognosis in patients with hypertensive intracerebral hemorrhage (P<0.05). ROC curve analysis showed that the AUC of plasma LPAR1 level for diagnosing poor prognosis in patients with hypertensive intracerebral hemorrhage was 0.857 (95%CI: 0.753-0.869), with a cutoff value of 3.68 μmol/L, with sensitivity and specificity of 81.3% and 85.6%, respectively.【Conclusion】 Plasma LPAR1 levels have certain predictive value for the prognosis of patients with hypertensive intracerebral hemorrhage, and can provide some reference for early clinical evaluation of patient prognosis.
Key wordsIntracranial Hemorrhage, Hypertensive    Receptors, Lysophosphatidic Acid/BL    Prognosis
收稿日期: 2022-08-26     
中图分类号:  R743.2  
通讯作者: *E-mail: xfy1979@163.com   
引用本文:   
刘涛, 张辉, 徐凡叶. 血浆溶血磷脂酸受体1水平对高血压脑出血患者预后的预测价值[J]. 医学临床研究, 2024, 41(1): 74-77.
LIU Tao, ZHANG Hui, XU Fanye. The Predictive Value of Plasma Lysophosphatidic Acid Receptor 1 Levels on the Prognosis of Hypertensive Intracerebral Hemorrhage Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 74-77.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.01.020     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I1/74
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn